BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Japan

iPS Cell Therapy: Is Japan the Market Leader?

January 7, 2021 By Cade Hildreth (CEO) 2 Comments

Although there are key players in multiple geographies worldwide, Japan has positioned itself as a hub for induced pluripotent stem cell (iPS cell) technology. iPS cells are made by reprogramming adult cells back into an embryonic-like state. Derived from skin or blood cells, they are not controversial.

[Read more…]

Filed Under: iPS Cells, Stem Cells Tagged With: cynata therapeutics, FUJIFILM, iPS cells, iPSC, Japan

World’s First Clinical Application of iPS Cells for Cardiac Disease

June 2, 2018 By Cade Hildreth (CEO) Leave a Comment

On 16 May, Nature News reported that “Japan’s health ministry gave doctors at Osaka University permission to take sheets of tissue derived from iPS cells and graft them onto diseased human hearts.” The team of Japanese doctors, led by cardiac surgeon Yoshiki Sawa at Osaka University, will use iPS cells to “create a sheet of 100 million heart-muscle cells.”

From preclinical studies in pigs, the team determined that thin sheets of cell grafts can improve heart function, likely through paracrine signalling. Paracrine signalling is a type of cell-to-cell communication through which cells “talk” to one another, often regulating inflammation, fibrosis (scarring), and and cellular recovery.

While the treatment will only be tested in three patients, a follow-up trial could enroll ten or more patients. Under Japan’s accelerated regulatory pathway for regenerative medicines (cell, gene and tissue products), Dr. Sawa’s iPS cell therapy could be conditionally marketed to the public if a follow-up trial demonstrated safety and an initial proof of efficacy.

Launched in late 2014, Japan’s fast-track system allows for regenerative therapies to receive conditional marketing authorization for up to 7 years, following confirmation of safety and an initial proof of efficacy in Japan in diseases that are serious and have a high unmet need. [Read more…]

Filed Under: iPS Cells, Stem Cell News Tagged With: cardiac, iPS cells, Japan

Japan to Supply Human Embryonic Stem Cells (hESC) for Clinical Research

May 29, 2018 By Cade Hildreth (CEO) Leave a Comment

Kyoto University has announced that it will start providing human embryonic stem cells (ES cells) by July 2018 to universities and companies within Japan for clinical trial applications. This is a world-first, as most countries have been hesitant to support wide-spread production and distribution of this controversial cell type.

Previously Japan limited the use of human embryonic stem cells to basic research, because the cells are produced from human embryos, making them a highly controversial cell type. In 2014, the Japanese government revised it guidelines, making possible the use human ES cells in clinical studies, as well as laboratory research. [Read more…]

Filed Under: iPS Cells, Stem Cell News Tagged With: ESC, iPS cells, Japan

Japan’s Laws Supporting Accelerated Pathways for Cell Therapies

December 30, 2017 By Cade Hildreth (CEO) Leave a Comment

Japan's Two Laws Supporting Accelerated Pathways for Cell Therapies

In late 2014, Japan passed two new laws that revolutionized the commercialization of cell therapies within the country by providing an accelerated pathway for product approvals. While there has been much discussion about these laws, few people have a clear understanding of the implications of these regulations on a global scale.

Below, we summarize the laws, identify their importance, and most importantly, speak to how Japan has become a “gateway country” for regenerative medicines. [Read more…]

Filed Under: Stem Cells Tagged With: cell therapy, Japan, regulation

ISCT Webinar on Cell and Gene Therapy (CGT) Products in Japan

November 18, 2017 By Cade Hildreth (CEO) Leave a Comment

ISCT Webinar CGT Japan

Have you heard of the recent regulatory changes surrounding cell and gene therapy (CGT) products in Japan?

These changes have greatly increased the interest in taking CGT clinical programs to Japan from development through commercialization. ISCT (International Society for Cellular Therapy) and FIRM (Forum for Innovative Regenerative Medicine) have created a partnership to facilitate the entry and development of future CGT products in Japan.

Robert Preti, PhD (General Manager of Hitachi Chemical’s Regenerative Medicine Business Sector) and Kazuchika Furuishi, PhD (Deputy General Manager) are joining a leading Japanese management consultant (Colin Novick) to discuss the challenges to consider and examples of solutions for successfully taking your clinical cell or gene therapy program to Japan.

On Wednesday, December 6, the webinar will explore the attractive regulatory changes in Japan, as well as:

  • Increased offshore filing activity
  • Challenges to consider
  • Successful CGT programs brought to Japan

Register now for the Hitachi Chemical Advanced Therapeutics Solutions, LLC sponsored webinar and learn from experts:

http://www.celltherapysociety.org/?page=wbnr_BMI

[Read more…]

Filed Under: Cell Therapy, Stem Cell News Tagged With: FIRM, ISCT, Japan

  • 1
  • 2
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.